OM Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 18.32%, SMA50 4.27%, SMA200 -60.37%). The stock’s 14-day RSI is 54.15 (neutral), while the ATR of 0.52 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -77.02% below its high and over 62.9% above its low. Average 10-day trading volume of 4.83 million shares is significantly above the 3-month average of 960.67 thousand, indicating heightened recent market interest.

Outset Medical, Inc. has 17.77 million shares outstanding. The public float is 11.27 million shares, elevated short interest at 12.27% of float. This equals 2.16 million shares. The short ratio is 7.49 days. Institutional investors hold 106.12% of the float. Insiders own 2.7%. Williamson Steven S. holds 320.35 thousand shares, Racine Jean-Olivier has 265.32 thousand shares and Trigg Leslie has 119.62 thousand shares. Over the past six months, insider transactions show net selling. They sold 6.76 thousand shares across 10 transactions.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Outset Medical, Inc. generated EPS of -$13.00 over the past year. Five-year average earnings growth is -4.06%. Wall Street analysts project EPS growth of 55.3% annually over the next five years. The latest quarter delivered EPS of -$0.84. The next quarter is forecast at -$0.67. Next year's EPS is expected at $27.66. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 4 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $22.00 to $14.00. The high target offers 335.64% upside. The low target suggests 177.23% downside. The mean target is $17.57. This offers 247.92% upside. Outset Medical, Inc. earnings surprise history is a mixed track record. The quarter that ended August 06, 2025, missed forecasts by -52.27%. The prior quarter beat by 234.02%. Over the last six quarters, Apple has recorded several small beats. These include 7.55% in May 08, 2024.

Outset Medical, Inc. (NASDAQ:OM) closed at $5.20 USD, gaining $0.15 (2.97%) from the previous close of $5.05. The stock is currently mid-range between its 52-week high and low $3.10 and $21.98. With a market capitalization of about $94.40 million, Outset Medical, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.07). Key stats such as the average daily volume over the past year has been around 991.26 thousand shares, volume is running light vs its 52-week average. Headquartered in San Jose, CA, Outset Medical, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Leslie L. Trigg, the company employs approximately 354 people and listed since September 15, 2020. Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis.

Outset Medical, Inc. trades at a P/E ratio of -1.06, slightly below the S&P 500 average, with a price-to-sales ratio of 0.79 and a price-to-book ratio of 0.65 suggesting the stock is closer to book value. The P/FCF stands at -1.76, also above market averages.

Our AI price prediction model suggests that Outset Medical, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.97%, with price expected at $5.20 by February 03, 2026, within a range of $4.53 to $5.86 3-Month Outlook: Projected fall of -97.62%, reaching $0.12 by April 16, 2026, with a range of $0.00 to $1.15. 1-Year Outlook: Projected loss of -13.27%, with price at $4.38 by January 15, 2027, within a range of $0.00 to $0.00.

Outset Medical, Inc. (NASDAQ:OM) shares are up 36.12% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Outset Medical, Inc. trading at a premium to the broader market with a P/E of -1.06. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $24.40, suggesting 383.17% upside. Our AI forecast model points to short-term strength (2.97% over two weeks), a medium-term fall (-97.62% over three months), and a longer-term loss (-13.27% over one year), with expected trading ranges indicating moderate volatility.